Related Experiment Video
Updated: May 22, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Buprenorphine: a newer drug for treating neonatal abstinence syndrome
1All Children's Hospital/Johns Hopkins Medicine, 501 Sixth Avenue South, Saint Petersburg, FL 33701, USA. sbell42104@aol.com
Abstract:
Neonates may be exposed to various legal and illicit substances during gestation, including cigarettes, alcohol, narcotics, benzodiazepines, antidepressants, and stimulants. Many of these substances can result in varying degrees of drug withdrawal after delivery. Polysubstance use can complicate the clinical evaluation of a newborn both in terms of assessment of withdrawal and treatment of symptoms. For the purpose of this column, the focus is on those infants with in utero narcotic exposure. The primary circumstances under which pregnant women use narcotics are illicit drug abuse, prescribed narcotic maintenance as treatment for abuse, and treatment of chronic pain conditions.
More Related Videos
09:29Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
05:13Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
Published on: February 28, 2025
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Pharmacokinetics in Pediatric Patients: Drug Excretion
Antidepressant Drugs: MAOIs and Other Agents
Drug Abuse and Addiction: Pharmacological Phenomena
Opioid Analgesics: Morphine and Other Natural Cogeners
Oral Drug Delivery Systems: Continuous-Release Systems